U.S. Markets open in 2 hrs 34 mins

University of Washington enrolls patients Cell Therapeutics' OPAXIO study

Cell Therapeutics, or CTI, announced that the University of Washington's, or UW, School of Medicine, Departments of Neurology and Neurosurgery, Division of Neuro-Oncology has begun enrolling patients in a randomized phase II clinical study comparing the combination of OPAXIO - paclitaxel poliglumex, PPX, CT-2103 - and radiation therapy, or RT, to the combination of temozolomide, or TMZ, and RT for patients with newly-diagnosed glioblastoma multiforme, or GBM, which is a poor-prognosis high-grade malignant brain tumor with an active gene called MGMT. MGMT is active in more than half of patients with glioblastoma and it substantially decreases the effectiveness of standard therapy with TMZ. This study is a multicenter trial initiated and led by the Neuro-Oncology department of the Brown University Oncology Research Group, or BrUOG, in Providence, Rhode Island. The first patient at UW recently has been enrolled.